STIM 주식 개요 상업 단계의 의료 기술 회사인 뉴로네틱스는 미국 및 전 세계의 신경 건강 장애 환자를 위한 제품을 설계, 개발 및 판매합니다. 자세한 내용
{"enabled":false,"variant":{"name":"disabled","enabled":false},"ready":false,"error":null}
생각, 링크 및 회사 내러티브를 캡처하세요.
가격 내역 및 성능
다음에 대한 주가 최고가, 최저가 및 변동 요약 Neuronetics 과거 주가 현재 주가 US$3.93 52주 최고치 US$5.07 52주 최저치 US$0.52 베타 2.17 1개월 변경 129.82% 3개월 변경 사항 544.69% 1년 변경 사항 19.09% 3년 변화 23.20% 5년 변화 20.18% IPO 이후 변화 -85.85%
최근 뉴스 및 업데이트
Industry Analysts Just Made A Dazzling Upgrade To Their Neuronetics, Inc. (NASDAQ:STIM) Revenue Forecasts Feb 10
Neuronetics, Inc. Unveils Two Significant Publications on TMS Therapy for Depression Jan 30
Neuronetics, Inc. Provides Earnings Guidance for the Full Year 2025 Jan 14
Neuronetics, Inc.'s (NASDAQ:STIM) Shares Leap 43% Yet They're Still Not Telling The Full Story Jan 11
Neuronetics (NASDAQ:STIM) Is Making Moderate Use Of Debt Jan 02 Neuronetics, Inc. (NasdaqGM:STIM) completed the acquisition of Greenbrook TMS Inc. (OTCPK:GBNH.F) from Madryn Health Partners II (Cayman Feeder), LP, fund managed by Madryn Asset Management, LP, 1315 Capital II, L.P. fund managed by 1315 Capital, LLC, Greybrook Health Inc. and others for $0.58 million. Dec 11
더 많은 업데이트 보기
Industry Analysts Just Made A Dazzling Upgrade To Their Neuronetics, Inc. (NASDAQ:STIM) Revenue Forecasts Feb 10
Neuronetics, Inc. Unveils Two Significant Publications on TMS Therapy for Depression Jan 30
Neuronetics, Inc. Provides Earnings Guidance for the Full Year 2025 Jan 14
Neuronetics, Inc.'s (NASDAQ:STIM) Shares Leap 43% Yet They're Still Not Telling The Full Story Jan 11
Neuronetics (NASDAQ:STIM) Is Making Moderate Use Of Debt Jan 02 Neuronetics, Inc. (NasdaqGM:STIM) completed the acquisition of Greenbrook TMS Inc. (OTCPK:GBNH.F) from Madryn Health Partners II (Cayman Feeder), LP, fund managed by Madryn Asset Management, LP, 1315 Capital II, L.P. fund managed by 1315 Capital, LLC, Greybrook Health Inc. and others for $0.58 million. Dec 11
Neuronetics, Inc. (NASDAQ:STIM) Analysts Just Slashed Next Year's Revenue Estimates By 12% Nov 18
Neuronetics, Inc. Provides Standalone Earnings Guidance for the Fourth Quarter and Full Year 2024 Nov 14
A Piece Of The Puzzle Missing From Neuronetics, Inc.'s (NASDAQ:STIM) 28% Share Price Climb Nov 05
Neuronetics, Inc. to Report Q3, 2024 Results on Nov 12, 2024 Oct 30
Neuronetics Receives Deficiency Letter from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirement under Nasdaq Listing Rule 5450(a)(1) Oct 06
Neuronetics Receives Deficiency Letter from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirement under Nasdaq Listing Rule 5450(a)(1) Oct 05
Neuronetics, Inc. Expands Health Policies Enhance Tms Therapy Access for Adolescents and Adults Sep 20 Neuronetics, Inc. (NasdaqGM:STIM) entered into a definitive arrangement agreement to acquire Greenbrook TMS Inc. (OTCPK:GBNH.F) from Madryn Health Partners II (Cayman Feeder), LP, fund managed by Madryn Asset Management, LP, 1315 Capital II, L.P. fund managed by 1315 Capital, LLC, Greybrook Health Inc. and others for $1 million. Aug 13
Investors Give Neuronetics, Inc. (NASDAQ:STIM) Shares A 60% Hiding Aug 13
Neuronetics, Inc. Provides Earnings Guidance for the Third Quarter and Full Year 2024 Aug 13
Neuronetics, Inc. to Report Q2, 2024 Results on Aug 12, 2024 Jul 29
Neuronetics, Inc. Announces Aetna Policy Update Expands TMS Availability for Adolescents with Depression Jul 23
Here's Why Shareholders May Want To Be Cautious With Increasing Neuronetics, Inc.'s (NASDAQ:STIM) CEO Pay Packet May 24
Humana Is First Commercial Payer to Address TMS Therapy Coverage for Adolescents May 16
The Neuronetics, Inc. (NASDAQ:STIM) First-Quarter Results Are Out And Analysts Have Published New Forecasts May 09
Neuronetics: Reality Set In May 09 Neuronetics, Inc. Provides Earnings Guidance for the Second Quarter of Fiscal Year 2024 May 09
First quarter 2024 earnings: EPS and revenues exceed analyst expectations May 08
Market Cool On Neuronetics, Inc.'s (NASDAQ:STIM) Revenues Pushing Shares 36% Lower May 08
Neuronetics (NASDAQ:STIM) Has Debt But No Earnings; Should You Worry? May 01
Neuronetics, Inc. to Report Q1, 2024 Results on May 07, 2024 Apr 24
Neuronetics, Inc. Announces the Publication of Significant Clinical Findings in Brain Stimulation: Basic, Translational, and Clinical Research in Neuromodulation Apr 11
Even With A 26% Surge, Cautious Investors Are Not Rewarding Neuronetics, Inc.'s (NASDAQ:STIM) Performance Completely Mar 17
Neuronetics, Inc. Provides Earnings Guidance for the First Quarter and Full Year 2024 Mar 07
Full year 2023 earnings released: US$1.05 loss per share (vs US$1.38 loss in FY 2022) Mar 06
Executive VP notifies of intention to sell stock Mar 01
President recently sold US$71k worth of stock Feb 28
President notifies of intention to sell stock Feb 23
Neuronetics, Inc. to Report Q4, 2023 Results on Mar 05, 2024 Feb 22
Neuronetics, Inc. to Report Q4, 2023 Results on Mar 05, 2024 Feb 21
Executive VP recently sold US$53k worth of stock Feb 20
Executive VP notifies of intention to sell stock Feb 17
Executive VP recently sold US$52k worth of stock Feb 16
Neuronetics Launches Latest Evolution in Its Trakstar® Patient Data Management System Feb 12
Executive VP notifies of intention to sell stock Feb 12
Neuronetics: Modest Improvements Are Not Enough Jan 30
President recently sold US$60k worth of stock Jan 15
Neuronetics, Inc. Revises Earnings Guidance for the Fourth Quarter and Full Year of 2023 Jan 09
Neuronetics, Inc. (NASDAQ:STIM) Soars 61% But It's A Story Of Risk Vs Reward Dec 19
Neuronetics Receives 510(K) Clearance for Neurosite Coil Placement Accessory Dec 19 Neuronetics, Inc. Announces Pharmaceuticals and Medical Devices Agency Approval in Japan Dec 04
New minor risk - Share price stability Nov 30
Neuronetics, Inc. Provides Revenue Guidance for the Fourth Quarter and Full Year 2023 Nov 09
Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind Nov 09
Neuronetics, Inc. to Report Q3, 2023 Results on Nov 07, 2023 Oct 25
Neuronetics, Inc. Announces the Launch of the NeuroStar Voices Portal Sep 14
Consensus EPS estimates upgraded to US$1.15 loss Aug 15 Neuronetics, Inc. Provides Revenue Guidance for the Third Quarter of 2023
Second quarter 2023 earnings: EPS exceeds analyst expectations Aug 09 Neuronetics, Inc. to Report Q2, 2023 Results on Aug 08, 2023 Jul 26
Neuronetics, Inc Announces Expanded TMS Therapy Access Through Aetna® Health Plans Jul 22
Neuronetics, Inc.'s (NASDAQ:STIM) Shares Not Telling The Full Story Jun 21
Neuronetics Receives 510(K) Clearance for Ocd Mt Cap for Neurostar Advanced Therapy Jun 13
First quarter 2023 earnings: EPS and revenues exceed analyst expectations May 10
Neuronetics, Inc. Provides Earnings Guidance for the Second Quarter and Full Year of 2023 May 10
Does Neuronetics (NASDAQ:STIM) Have A Healthy Balance Sheet? May 10
Executive VP recently sold US$58k worth of stock Mar 16
Executive VP notifies of intention to sell stock Mar 10
Price target decreased by 10% to US$8.67 Mar 08
President recently sold US$214k worth of stock Feb 19
President notifies of intention to sell stock Feb 17
Neuronetics Announces Elevation of Sara Grubbs to SVP, Chief Revenue Officer Feb 17
High number of new directors Feb 01
Neuronetics, Inc. Announces Data Confirming Efficacy in Treating Anxious Depression with NeuroStar(R) Advanced Therapy for Mental Health Jan 19
Neuronetics, Inc. Revised Revenue Guidance for the Fourth Quarter and Full Year of 2022 Jan 10
Neuronetics, Inc. Appoints Joseph H. Capper to Its Board of Directors and as Member of the Audit Committee, Effective January 1, 2023 Dec 30
Consensus estimates of losses per share improve by 10% Nov 16
Neuronetics, Inc. Announces New Advancements of NeuroStar Advanced Therapy System Nov 15
Third quarter 2022 earnings: EPS and revenues exceed analyst expectations Nov 10
Neuronetics, Inc. Provides Earnings Guidance for the Fourth Quarter and Full Year of 2022 Nov 09
President exercised options to buy US$341k worth of stock. Oct 26
Neuronetics, Inc. to Report Q3, 2022 Results on Nov 08, 2022 Oct 26
Neuronetics, Inc. Launches Innovations to Neurostar Advanced Therapy’s Proprietary Trakstar Platform Sep 27
Neuronetics: Growth To Capture, But Fairly Priced Sep 06
Is Neuronetics (NASDAQ:STIM) Using Debt Sensibly? Sep 06
Neuronetics gets FDA nod for its D-Tect accessory product for use to treat depression Aug 29
Bruce J. Shook Notifies the Board of Directors of Neuronetics, Inc. to Resign from the Board Effective as of October 31, 2022 Aug 27
Second quarter 2022 earnings: EPS and revenues exceed analyst expectations Aug 03
Neuronetics, Inc. Provides Earnings Guidance for the Quarter Ending September 30, 2022 and for the Year Ending December 31, 2022 Aug 03
Neuronetics GAAP EPS of -$0.39 beats by $0.02, revenue of $16.3M beats by $0.84M , revises FY guidance Aug 02
Senior VP notifies of intention to sell stock Jul 30
President recently sold US$236k worth of stock Jul 21 Neurostics Inc. Receives U.S. Food and Drug Administration Clearance for Treatment of Anxious Depression
Neuronetics stock soars 30% as FDA clears NeuroStar system for anxious depression Jul 19
President notifies of intention to sell stock Jul 16 주주 수익률 STIM US Medical Equipment US 마켓 7D 13.9% -0.2% 0.2% 1Y 19.1% 14.4% 23.1%
전체 주주 수익률 보기
수익률 대 산업: STIM 지난 1년 동안 14.4 %를 반환한 US Medical Equipment 산업을 초과했습니다.
수익률 대 시장: STIM 지난 1년 동안 23.1 %를 반환한 US 시장보다 저조한 성과를 냈습니다.
가격 변동성 Is STIM's price volatile compared to industry and market? STIM volatility STIM Average Weekly Movement 24.0% Medical Equipment Industry Average Movement 8.1% Market Average Movement 5.9% 10% most volatile stocks in US Market 18.3% 10% least volatile stocks in US Market 3.0%
안정적인 주가: STIM 의 주가는 지난 3개월 동안 US 시장과 비교해 변동성이 컸습니다.
시간에 따른 변동성: STIM 의 주간 변동성 은 지난 1년 동안 18% 에서 24% 로 증가했습니다.
회사 소개 상업 단계의 의료 기술 회사인 뉴로네틱스는 미국 및 전 세계의 신경 건강 장애 환자를 위한 제품을 설계, 개발 및 판매합니다. 이 회사는 주요 우울 장애를 가진 성인 환자를 치료하기 위한 비침습적이고 비체계적인 사무실 기반 치료인 NeuroStar 고급 치료 시스템을 제공합니다. 뉴로스타 어드밴스드 테라피 시스템은 경두개 자기 자극을 사용하여 기분과 관련된 뇌의 특정 영역을 자극하도록 설계된 전류를 유도하는 펄스형 MRI 강도의 자기장을 생성합니다.
자세히 보기 Neuronetics, Inc. 기본 사항 요약 Neuronetics 의 수익과 매출은 시가총액과 어떻게 비교하나요? STIM 기본 통계 시가총액 US$214.82m 수익(TTM ) -US$36.42m 수익(TTM ) US$72.71m
수익 및 수익 최신 수익 보고서의 주요 수익성 통계(TTM) STIM 손익 계산서(TTM ) 수익 US$72.71m 수익 비용 US$15.77m 총 이익 US$56.94m 기타 비용 US$93.36m 수익 -US$36.42m
주당 순이익(EPS) -0.65 총 마진 78.31% 순이익 마진 -50.09% 부채/자본 비율 490.4%
STIM 의 장기적인 성과는 어땠나요?
과거 실적 및 비교 보기
기업 분석 및 재무 데이터 현황 데이터 마지막 업데이트(UTC 시간) 기업 분석 2025/02/11 11:48 장 마감 주가 2025/02/11 00:00 수익 2024/09/30 연간 수익 2023/12/31
데이터 소스 기업 분석에 사용된 데이터는 S&P Global Market Intelligence LLC의 데이터입니다. 이 보고서를 생성하기 위해 분석 모델에 사용된 데이터는 다음과 같습니다. 데이터는 정규화되어 있으므로 소스가 제공되기까지 지연이 발생할 수 있습니다.
패키지 데이터 기간 미국 소스 예시 * 회사 재무 10년 애널리스트 컨센서스 추정치 +3년 시장 가격 30년 소유권 10년 관리 10년 주요 개발 사항 10년
* 미국 증권의 경우, 미국 외 지역의 규제 양식 및 출처는 미국 증권의 예를 사용했습니다.
명시되지 않는 한 모든 재무 데이터는 1년을 기준으로 하지만 분기별로 업데이트됩니다. 이를 후행 12개월(TTM) 또는 최근 12개월(LTM) 데이터라고 합니다. 자세히 알아보기 .
분석 모델 및 눈송이 이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 Github 페이지에서 확인할 수 있으며, 보고서 사용 방법에 대한 가이드와 튜토리얼도 유튜브에서 확인할 수 있습니다.
Simply 월스트리트 분석 모델을 설계하고 구축한 세계적인 수준의 팀에 대해 알아보세요.
산업 및 부문 메트릭 업계 및 섹션 지표는 Simply Wall St에서 6시간마다 계산되며, 자세한 내용은 Github에서 확인할 수 있습니다.
애널리스트 출처 Neuronetics, Inc. 6 애널리스트 중 3 애널리스트가 보고서의 입력 자료로 사용된 매출 또는 수익 추정치를 제출했습니다. 애널리스트의 제출 자료는 하루 종일 업데이트됩니다.
분석가 교육기관 Michael Gorman BTIG William Plovanic Canaccord Genuity David Turkaly JMP Securities
3 더 많은 분석가 보기 
